Witt K, van Dorn R, Fazel S. Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS ONE. 2013;8:e55942.
Fazel S, Gulati, G, Linsell L, Geddes JR, Grann M Schizophrenia and violence: systematic review and meta-analysis. PLoS Medicine. 2009;6:e1000120.
Large MM, Nielssen O. Violence in first-episode psychosis: a systematic review and meta-analysis. Schiz Res. 2011;125:209–20.
Hodgins S, Riaz M. Violence and phases of illness: differential risk and predictors. Eur Psychiatry. 2011;26:518–24.
Volavka J, Citrome L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull. 2011;36:921–9.
Taylor PJ. Psychosis and violence: stories, fears and reality. Can J Psychiatry. 2008;53:647–59.
Hodgins S. Violent behavior among people with schizophrenia: a framework for investigations of causes, and effective treatment, and prevention. Philos Trans R Soc. 2008;363:2505–18.
Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15:1351–71.
Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry. 1998;59:8–14.
Spivak B, Mester R, Wittenberg N, Maman Z, Weizman A. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clin Neuropharmacol. 1997;20:442–6.
Aleman A, Kahn RS. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur Neuro. 2001;11:289–93.
Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry. 1999;60:52–60.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.
Hedlund JL, Vieweg BW. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. J Oper Psychiatry. 1980;11:48–65.
Knezevic V, Mitrovic D, Drezgic-Vulkic S, Knezevic J, Ivezic A, Siladji-Mladenovic D et al. Prevalence and correlates of aggression and hostility in hospitalized schizophrenic patients. J Interpers Violence. 2015;32:151-163.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
Lindenmayer J-P, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia. J Nerv Ment Dis. 1994;182:631–8.
Chengappa KNR, Goldstein JM, Greenwood M, John V, Levine J. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther. 2003;25:530–41.
Dunlap WP, Cortina JM, Vaslow JB, Burke MJ. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol Methods. 1996;1:170–7.
Borenstein M, Hedges LV, Higgings T, Rothstein HR. Introduction to meta-analysis. Chapter 12. Chichester, UK: Wiley; 2009.
Borenstein M, Higgings JPT, Hedges LV, Rothstein HR. Basics of meta-analysis: I2 is not an absolute measure of heterogeneity. Res Synth Methods. 2017;8:5–18.
Borenstein M, Hedges L, Higgings J, Rothstein H. Comprehensive meta analysis version. Englewood, NJ: Biostat Inc; 2005. p. 2.
Gardner DM, Murphy AL, O’Donnel H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic drugs. Am J Psychiatry. 2010;167:686–93.
Min SK, Rhee CS, Kim C-E, Kang D-Y. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J. 1993;34:179–90.
Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166:712–26.
Citrome L, Volavka J, Czobor P, Brook S, Loebel A, Mandel FS. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry. 2006;67:4.
Volavka J, Czobor P, Derks E, Bitter I, Libiger J, Kahn RS, et al. Efficacy of antipsychotic drugs against hostility in the European first-episode schizophrenia trial (EUFEST). J Clin Psychiatry. 2011;72:955–61.
Krakowski MI, Czobor P, Citrome L, Bark N, Cooper MA. Atypical antipsychotics in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006;63:622–9.
Krakowski MI, Czobor P, Nolan KA. Atypical antipsychotics, neurocognitive deficits and aggression in schizophrenic patients. J Clin Psychopharmacol. 2008;28:485–93.
Swanson JW, Schwartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull. 2004;30:1.
Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone or haloperidol. J Clin Psychopharmacol. 2004;24:225–8.
Brieden T, Ujeyl M, Naber D. Psychopharmacological treatment of aggression in schizophrenic patients. Pharmacopsychiatry. 2002;35:83–9.
Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: multiple-treatments meta-analysis. Lancet. 2013;382:14.
Correll CU, Yu X, Xiang Y, Kane JM, Masand P. Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry. 2017;29:92–107.
Gallitano-Mendel A, Wozniak DF, Pehek EA, Milbrandt J. Mice lacking the immediate early gene Egr3 respond to the anti-aggressive effects of clozapine yet are relatively resistant to its sedating effects. Neuropsychopharmacology. 2008;33:1266–75.
Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev. 2001;7:283–304.
Lo CH, Tsai GE, Liao CH, Wang MY, Chang JP, Tsuang HC, et al. Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. Biol Psychol. 2010;83:79–83.
Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract. 2008;62:1237–45.
Gillies D, Sampson S, Beck A, Rathbone J. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews 2013.
Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994;151:20–6.
Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, McEvoy J, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv. 2001;52:1510–4.
Claghorn J, Honingfeld G, Abuzzahab F, Wang R, Steinbook R, Tuason V, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol. 1987;7:377–84.
Czobor P, Volavka J, Meibach R. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol. 1995;15:243–9.
Delcker A, Schoon ML, Oczkowski B, Gaertner HJ. Pharmacopsychiatry. 1990;23:125-30.
Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al. Maintenance treatment with risperidone of low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German research network on schizophrenia. J Clin Psychiatry. 2007;68:1763–74.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry. 1988;45:789–96.
Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia. Arch Gen Psychiatry. 2001;58:965–72.
Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry. 2001;62:17–21.
Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American Trials. J Clin Psychiatry. 1997;58:538–46.
Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry. 2003;150:1405–12.
Müller MJ, Wetzel H, Eich F-X, Rein W, Puech A, Benkert O. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2002;22:554–60.
Volavka J, Czobor P, Citrome L, Van Dorn RA. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinial Antipsychotics Trials of Intervention Effectiveness (CATIE) study. CNS Spectr. 2014;19:374–81.